- Home
- INCY vs OMC Comparison
INCY vs OMC Comparison
Compare INCY & OMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- OMC
- Stock Information
- Founded
- INCY 1991
- OMC 1944
- Country
- INCY United States
- OMC United States
- Employees
- INCY N/A
- OMC N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- OMC Advertising
- Sector
- INCY Health Care
- OMC Consumer Discretionary
- Exchange
- INCY Nasdaq
- OMC Nasdaq
- Market Cap
- INCY 13.0B
- OMC 14.0B
- IPO Year
- INCY 1993
- OMC N/A
- Fundamental
- Price
- INCY $86.92
- OMC $76.30
- Analyst Decision
- INCY Buy
- OMC Buy
- Analyst Count
- INCY 20
- OMC 7
- Target Price
- INCY $79.06
- OMC $94.43
- AVG Volume (30 Days)
- INCY 1.9M
- OMC 3.7M
- Earning Date
- INCY 07-29-2025
- OMC 10-14-2025
- Dividend Yield
- INCY N/A
- OMC 3.67%
- EPS Growth
- INCY 900.04
- OMC N/A
- EPS
- INCY 4.37
- OMC 7.00
- Revenue
- INCY $4,584,996,000.00
- OMC $15,910,800,000.00
- Revenue This Year
- INCY $13.53
- OMC $4.74
- Revenue Next Year
- INCY $10.38
- OMC $10.28
- P/E Ratio
- INCY $19.90
- OMC $10.91
- Revenue Growth
- INCY 18.87
- OMC 5.21
- 52 Week Low
- INCY $53.56
- OMC $68.37
- 52 Week High
- INCY $87.06
- OMC $107.00
- Technical
- Relative Strength Index (RSI)
- INCY 80.83
- OMC 59.36
- Support Level
- INCY $76.45
- OMC $71.80
- Resistance Level
- INCY $79.43
- OMC $76.62
- Average True Range (ATR)
- INCY 2.57
- OMC 1.67
- MACD
- INCY 1.01
- OMC 0.33
- Stochastic Oscillator
- INCY 99.13
- OMC 93.05
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, and ad placement. In addition, Omnicom provides outsourced public relations and other communications services. The firm operates globally, providing services in more than 70 countries; it generates more than half of its revenue in North America and nearly 30% in Europe. The firm announced plans to merge with Interpublic Group in December 2024, pending regulatory approval.